Paulo Victor Sgobbi de Souza

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes

Antônio Edvan Camelo-Filho, André Macedo Serafim da Silva, Eduardo de Paula Estephan et al. · Frontiers in Neurology · 2020 · 105 citations · Full text

Autoimmune Disease, Intensive Care Unit, Immunodeficiencies +13

Clinical and radiological profile of patients with spinal muscular atrophy type 4

Paulo Victor Sgobbi de Souza, Wladimir Bocca Vieira de Rezende Pinto, Aracelly R.F. Ricarte et al. · European Journal of Neurology · 2020 · 44 citations

Intragenic variants in the <i>SMN1</i> gene determine the clinical phenotype in 5q spinal muscular atrophy

Rodrigo de Holanda Mendonça, Ciro Matsui, Graziela Jorge Polido et al. · Neurology Genetics · 2020 · 42 citations · Full text

Clinical and molecular findings in a cohort of <i>ANO5</i>‐related myopathy

André Macedo Serafim da Silva, Antônio R. Coimbra‐Neto, Paulo Victor Sgobbi de Souza et al. · Annals of Clinical and Translational Neurology · 2019 · 39 citations · Full text